Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly and Company (NYSE:LLY ) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Kevin Hern - Vice President of Investor Relations Dave Ricks - Chair & Chief Executive Officer Anat Ashkenazi - Chief Financial Officer Dan Skovronsky - Chief Scientific Officer & Chief Medical Officer Mike Mason - President of Lilly Diabetes Ilya Yuffa - President of Lilly International Jake Van Naarden - Chief Executive Officer, Loxo Oncology, Lilly & President, Lilly Oncology Conference Call Participants Geoff Meacham - Bank of America Chris Schott - JPMorgan Seamus Fernandez - Guggenheim Louise Chen - Cantor Terence Flynn - Morgan Stanley Steve Scala - Cowen Andrew Baum - Citi Kerry Holford - Berenberg Robin Kinesis - Tuas Securities Colin Bristow - UBS Operator And ladies and gentlemen, thank you for standing by. Welcome to the Lilly Q2 2022 Earnings Conference Call.

Eli Lilly and Company (LLY) CEO Dave Ricks on Q2 2022 Results - Earnings Call Transcript

Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022.

Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance

Shares of Eli Lilly & Co (NYSE: LLY) are in the red this morning after the pharmaceutical giant reported weaker-than-expected results for its fiscal second quarter. Key takeaways from Eli Lilly Q2 results Net income printed at $952.5 million versus the year-ago $1.39 billion Per-share earnings of $1.05 were well below last year's $1.

Eli Lilly Q2 results: its Alzheimer's drug could be ‘the biggest drug in history'

INDIANAPOLIS , Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties.

Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results

Lilly (LLY) delivered earnings and revenue surprises of -30.56% and 5.91%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Lags Q2 Earnings and Revenue Estimates

Eli Lilly missed second-quarter expectations and slashed its full-year outlook Thursday, leading LLY stock to crumble. The post Eli Lilly Slashes Guidance After 'Significantly' Missing Quarterly Estimates; Shares Dive appeared first on Investor's Business Daily.

Eli Lilly Slashes Guidance After 'Significantly' Missing Quarterly Estimates; Shares Dive

Eli Lilly & Co. LLY, -1.99% shares fell 3.6% in pre-market trading on Thursday after the company reported second-quarter results that came in below Wall Street's forecast. The company's stock ended Wednesday's session down 2% at $313.83.

Eli Lilly stock falls 3% after Q2 top and bottom line results miss Wall Street's forecast

The company cuts its fiscal-year earnings per share guidance by 25 cents because of foreign-exchange headwinds.

Eli Lilly Stock Sinks After Fiscal-Year Forecast Is Slashed

Eli Lilly and Co reported a 31% fall in quarterly profit on Thursday, hurt by lower prices of diabetes drug Humalog and Insulin Lispro injection.

Eli Lilly quarterly profit falls 31% on diabetes drug weakness

Lilly's revenue in Q2 2022 decreased 4%. On a constant currency basis, revenue decreased 1% as lower realized prices and lower Alimta revenue following the entry of generics more than offset volume growth from key growth products.

Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements

Catalent

HEICO

Cheniere Energy

Lantheus Holdings

New Fortress Energy

Ollie's Bargain Outlet Hlds

Quanta Services

UnitedHealth Group

Vertex Pharmaceuticals

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on Investor's Business Daily.

Watch These Leaders With Earnings Due, Buy Zones In Focus

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline

Pharmaceuticals giant Eli Lilly has formed a three-weeks tight pattern within the buy zone of flat base just before earnings. The post Eli Lilly Stock Nears A New Buy Point appeared first on Investor's Business Daily.

Eli Lilly Stock Nears A New Buy Point

Pfizer

Both stocks could be winners for long-term investors, but one gets the nod when it comes to dividends.

Better Dividend Stock: Pfizer or Eli Lilly?

Assurant

FTI Consulting

Grocery Outlet

Incyte

Coca-Cola

Leidos Hld

Neurocrine Biosciences

T-Mobile US

The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just months away, it's likely the volatility is going to remain for the time being. Investors looking for a smoother market ride should consider buying low-volatility stocks as a way to manage risk.

10 Best Low-Volatility Stocks to Buy Now

AbbVie

Biogen

Bristol-Myers

Merck

The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-tier drug companies in the second half, including interest rates, federal drug pricing actions and scrutiny by the Federal Trade Commission.

2nd-Quarter Earnings Results Could Impact Drug Company Shares

Novo Nordisk

An obese population could drive competition toward a valuable market.

2 Pharma Giants With Momentum That Could Carry Through 2030

Schaeffer's Investment Research was built from scratch on Bernie Schaeffer's vision of providing accessible professional-grade trading information to retail traders.

Red-Hot Eli Lilly Stock Has Room to Run

INDIANAPOLIS , July 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement

Amgen

Gilead Sciences

ImmunityBio

Viatris

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

7 Best Pharmaceutical Stocks to Buy Now

Eli Lilly has seen very strong momentum on the operational front, but certainly in its shares as well. Expectations of new approvals have pushed up valuations a great deal, as the company has quite a lot to prove at this valuation.

Eli Lilly: Powering Ahead, But Too Strong

General Mills

You can find winners even in today's stock market.

As Markets Churn, These 2 Stocks Just Hit All-Time Highs

Regeneron Pharmaceuticals

Could health care stocks be the best stocks to jump on in the second half of 2022?

What Stocks To Buy Today? 5 Health Care Stocks To Know

AstraZeneca

Roche Holding AG

Sanofi

Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company, sometimes sending it up, sometimes down.

3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks

Jazz Pharmaceuticals

What else do these companies have in store?

News for Eli Lilly Stock (LLY)